Table 1 Study characteristics of studies investigating the prognostic relevance of HPV-16
Author | Year | Country | Total number of patients | Mean age | Clinical stage | Treatment | Number of patients with HPV-16 positive | Number of patients with HPV-18 negative | Median DFS | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Yat Ming Lau | 2015 | Hong Kong, China | 236 | 54.4 | I-III | radiotherapy+/−chemotherapy | 142 | 94 | 73.2% vs. 81.2%, HR: 1.54, 95% CI = 0.93–2.56 | NA | 71.6% vs. 81.7%, HR: 0.99, 95% CI = 0.64–1.55 |
Dong Hang | 2017 | China | 306 | 48 | I-IV | surgery alone, surgery plus adjunctive chemotherapy, radiotherapy or chemoradiotherapy, concurrent chemoradiotherapy, chemotherapy or radiotherapy only. | 186 | 120 | NA | NA | HR: 0.36, 95% CI = 0.18–0.74, P = 0.005 |
Mamiko Onuki | 2018 | Japan | 137 | 49.2 | I-IV | Surgery+radiotherapy | 59 | 78 | NA | NA | HR: 0.42, 95% CI = 0.15–1.04, P = 0.06 |
Byoung Hyuck Kim | 2019 | Korea | 298 | 48 | I-IV | radiotherapy | 164 | 127 | NA | 77.6 vs. 57.7%, P = 0.022 | HR: 0.558, 95% CI = 0.326–0.955, P = 0.033 |
Sun-Hye Yang | 2014 | Korea | 116 | NA | I-IIA | surgery | 49 | 67 | NA | HR: 1.33, 95% CI = 0.31–5.67, P = 0.70 | Not significant |
Rossana de Arau ́jo Cata ̃o Zampronha | 2013 | Brazil | 86 | 40 | I | Surgery+radiotherapy | 30 | 56 | HR: 1.104, 95% CI = 0.243–5.007 | NA | NA |